Table 5.

Meta-analysis results of outcomes reported by studies comparing TAC + AZA vs. TAC ^a.

Outcome	Study Design (N)	Time in months	Relative Risk b (95% CI)	Statistics c
				p	I2
Total Infections	RCT [36,38] (720)	12	0.99 (0.82, 1.20)	0.94	0
Leukopenia	RCT [36,38] (720)	12	8.41 (3.36, 21.02)	<0.01	0
Diabetes mellitus	RCT [36,38] (720)	12	0.85 (0.41, 1.76)	0.67	0
Hypertension	RCT [36,38] (720)	12	0.83 (0.65, 1.06)	0.13	0
Tremor	RCT [36,38] (720)	12	0.96 (0.68, 1.35)	0.82	0
Withdraw	RCT [36,38] (720)	12	10.39 (4.40, 24.56)	<0.01	0

^a Results reaching statistical significance are in bold font. ^b Relatives risk values of <1 favor treatment with Antiproliferative Agent + TAC. ^c p: p-value for relative risk estimation; I²: test for heterogeneity